Skip to main content
SpringerLink
Log in

Der heutige Stand der Therapie des Korpuskarzinoms

  • Conference paper
Gießener Gynäkologische Fortbildung 1987

Zusammenfassung

Das Karzinom des Endometriums, das sog. Korpuskarzinom, ist heute eines der häufigsten Karzinome der Frau. In Baden-Württemberg steht es mit 25–32 Neuerkrankungen pro 100000 Frauen jährlich nach dem Mammakarzinom an 2. Stelle der Krebserkrankungen der Frau überhaupt.

Herrn Prof.Dr.med.Dr.med.h.c.G.W.Löhr zum 65. Geburtstag gewidmet

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aalders J, Abeler V, Kolstadt P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 56: 419–427

    PubMed  CAS  Google Scholar 

  • Annual report on the results of treatment in gynecological cancer, vol 19. Stockholm, 1985

    Google Scholar 

  • Ayoub J, Audet-Lapointe P, Méthot Y, et al (1985) Effectiveness of cyclical hormonal therapy in endometrial cancer and its correlation with estrogen-receptor status. Proc Am Soc Clin Oncol 4:114

    Google Scholar 

  • Bauknecht T (1986) Wachstumsfaktoren und deren Rezeptoren als Prognosefaktoren beim Ovarialkarzinom. In: Pfleiderer A (Hrsg) Maligne Tumoren der Ovarien Klinik, Diagnostik und Therapie. Enke, Stuttgart, S 150–153

    Google Scholar 

  • Bruckner HW, Deppe G (1977) Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. Obstet Gynecol 50: 105

    Google Scholar 

  • Burghardt, E, Winter R, Lahousen M, Stettner H (1986) Die pelvine Lymphonodektomie bei der operativen Behandlung des Ovarialkarzinoms. Ber Gynaekol Geburtshilfte 122: 845–846

    Google Scholar 

  • Carlson JA Jr, Allegra JC, Day TG, Wittliff JL (1984) Tamoxifen and endometrial carcinoma. Am J Obstet Gynecol 149: 149–153

    PubMed  Google Scholar 

  • Christopherson W (1982) Prognostic factors in carcinoma of the endometrium. 18th Annual Meeting, Society Gynecology Oncology, Marco Island, Fla January 19th, 1982

    Google Scholar 

  • Creasman WT (1985a) Endometrial cancer: pathogenesis and its implications XI. FIGO-WeltKongreß, Berlin, 17.9. 85

    Google Scholar 

  • Creasman WT (1985b) Receptors in cancer of the endometrium. XI. FIGO-Welt-Kongreß, Berlin, 18.9. 85

    Google Scholar 

  • Creasman WT, Weed JC Jr (1981) Carcinoma of endometrium (FIGO stages I a II): clinical features and management. In: Coppleson M (ed) Gynecologic oncology. Churchill Livingstone, Edinburgh, pp 562–877

    Google Scholar 

  • Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, Lee JH, Watring W (1984) Multi-drug treatment of advanced and recurrent endometrial carcinoma. A gynecologic oncology group study. Obstet Gynecol 63: 719–726

    CAS  Google Scholar 

  • Huber H, Husslein P, Michalica W, Wagenbichler P (1984) Radiosensitizing effect of medroxyprogesterone acetate on endometrial cancer cells in vitro. Cancer 54: 999–1001

    Article  PubMed  CAS  Google Scholar 

  • Kaiser R (1959) Die Wirkung von Gestagenen beim Korpuskarzinom. Arch Gynäkol 193: 195–199

    Article  PubMed  CAS  Google Scholar 

  • Kleine W (1985) Die thymusaplastische nu/nu-Maus als in-vivo-Testmodell. Möglichkeiten und Grenzen am Beispiel der gynäkologischen Onkologie. Aktuelle Onkologie 17. Zuckschwerdt, München

    Google Scholar 

  • Kleine W, Koenig P, Geyer H, Pfleiderer A (1985) Clinical, prognostic, and therapeutic aspects of steroid receptors in endometrial cancer. Arch Gynecol 237: 273

    Google Scholar 

  • Kleine W, Geyer H, Pfleiderer A (1986) Prognostic relevance of estrogen-and progesterone receptors in endometrial cancer. J Cancer Res Clin Oncol [Suppl] 111: 132

    Article  Google Scholar 

  • Lovecchio JL, Averette HE, Lichtinger M, Townsend PA, Girtanner RW, Fenton AN (1984) Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cisplatinum, and megestrolacetate. Obstet Gynecol 63: 557–560

    PubMed  CAS  Google Scholar 

  • Luciani L, Oriana S, Spatti G, et al (1984) Hormonal and receptor status in postmenoausal women with endometrial carcinoma before and after treatment with tamoxifen. Tumori 70: 189–192

    PubMed  CAS  Google Scholar 

  • Morrow CP, Creasman WT, Homesley H, Wilbanks G, Bundy B (1984) Recurrence in endometrial carcinoma as a function of extended surgical staging data. Gynecol Oncol 17: 262–263

    Article  Google Scholar 

  • Mortel R, Zaino R, Satyaswaroop PG (1984) Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Cancer 53: 113–116

    Article  PubMed  CAS  Google Scholar 

  • Neumann G (1986) Krebsregister Baden-Württemberg 1984. Krebsverband Baden-Württemberg eV, Stuttgart

    Google Scholar 

  • Pfleiderer A (1980) Die Klinik der gynäkologischen Krebskrankheiten. Häufigkeit, Therapie, Rezidivvorkommen und -lokalisation. In: Pfleiderer A, Eissenhauer W (Hrsg) Probleme der Krebsnachsorge. Beiträge zur Onkologie, Bd 4. Karger, Basel, S 12–30

    Google Scholar 

  • Pfleiderer A (1981) Die Kombination von Operation und Strahlentherapie aus der Sicht des Operateurs beim Endometrium-und Ovarialkarzinom. In: Wannenmacher M (Hrsg) Kombinierte chirurgische und radiologische Therapie maligner Tumoren. Urban & Schwarzenberg, München, S 255–266

    Google Scholar 

  • Pfleiderer A, Kleine W (1986) Risk factors of endometrial carcinoma. In: Bolla M et al (eds) Endometrial cancers, 5th Cancer Res Workshop Grenoble ( 1985 ). Karger, Basel, pp 12–21

    Google Scholar 

  • Pfleiderer A, Kleine W, Koenig P, Geyer H (1984) Hormonal receptors in endometrial cancer. Analysis of clinical prognosis and risk factors. In: Wolff JP, Scott JS (eds) Hormones and sexual factors in human cancer etiology. Elsevier, NewYork, pp 35–46

    Google Scholar 

  • Rendina GM, Donadio C, Fabri M, Mazzoni P, Nazzicone P (1984) Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 17: 285–291

    Article  PubMed  CAS  Google Scholar 

  • Schwartz PE, Mac Lusky N, Naftolin F, Eisenfeld A (1983) Tamoxifen-induced increase in cytosol progestinreceptor levels in a case of metastatic endometrial cancer. Gynecol Oncol 16: 41–48

    Article  PubMed  CAS  Google Scholar 

  • Seltzer V, Vogl SE, Kaplan BH (1984) Adriamycin and cis-diamminedichloroplatinum in the treat-ment of metastatic endometrial andocarcinoma. Gynecol Oncol 10: 308–313

    Article  Google Scholar 

  • Slavik M, Petty WM, Blessing JA, Creasman WT, Homesley HD (1984) Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a gynecologic oncology group study. Cancer Treat Rep 68: 809–811

    PubMed  CAS  Google Scholar 

  • Thigpen JT, Blessing JA, Di Saia PJ, Ehrlich C (for the Gynecologic Oncology Group) (1985) A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 4: 115

    Google Scholar 

  • Thigpen JT, Blessing JA, Lagasse LD, Di Saia PJ, Homesley HD (1984) Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A gynecologic oncology group study. Am J Clin Oncol 7: 253–256

    Google Scholar 

  • Thigpen JT, Morrow CP, Blessing JA (1986) Adjuvant chemotherapy in high-risk endometrial carcinoma. The gynecologic oncology group experience. In: Bolla M et al (eds) Endometrial cancers. Karger, Basel, pp 223–232

    Google Scholar 

  • Thigpen JT, Morrow CP, Blessing JA (1986) Chemotherapy in advanced or recurrent endometrial carcinoma. Gynecologic Oncology Group Studies. In: Bolla M et al (eds) Endometrial cancers. Karger, Basel, pp 256–266

    Google Scholar 

  • Trope C (1986) Flow cytometric DNA analysis of normal and cancerous human endometrium and cytological-histopathological correlations. Vortrag: 36th Annual Meeting Soceity Pelvic Surgeons. Newport Beach, Nov 1986

    Google Scholar 

  • Trope C, Johnsson JE, Simonsen E, Christiansen H, Cavallin-Stahl E, Horvath G (1984) Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 149: 379–381

    PubMed  CAS  Google Scholar 

  • Volm M, Brueggemann A, Guenther M, Kleine W, Pfleiderer A, Vogt-Schaden M (1985) Prognostic relevance of ploidy, proliferation and resistance-predictive tests in ovarian carcinoma. Cancer Res 45: 5180–5185

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Pfleiderer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Frauenklinik und Hebammenlehranstalt, Justus-Liebig-Universität, Klinikstr. 32, D-6300, Gießen, Germany

    Wolfgang Künzel (Gf. Direktor) (Gf. Direktor)

  2. Frauenklinik, Justus-Liebig-Universität, Klinikstr. 32, D-6300, Gießen, Germany

    Holger Gips

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Pfleiderer, A. (1987). Der heutige Stand der Therapie des Korpuskarzinoms. In: Künzel, W., Gips, H. (eds) Gießener Gynäkologische Fortbildung 1987. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72704-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72704-7_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-17851-4

  • Online ISBN: 978-3-642-72704-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation